Exelixis Announces Key Additions to Drug Discovery Team SOUTH SAN FRANCISCO, Calif., Jan 29, 2001 /PRNewswire via COMTEX/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced the addition of four key members to its scientific staff: Peter Lamb, Ph.D., as Senior Director of Molecular Pharmacology and Structural Biology; Kirk McMillan, Ph.D., Director of New Lead Discovery; John Nuss, Ph.D., Senior Director of Chemistry; and Yifan Zhai, M.D., Ph.D., Director of Pharmacology.
"I am pleased to welcome Peter, Kirk, John, and Yifan to Exelixis and am confident that their collective experience and expertise will further enhance our rapidly expanding drug discovery program," stated George A. Scangos, Ph.D., president and chief executive officer of Exelixis, Inc. "The addition of these high quality individuals to our talented team, in combination with our leadership position in genetics, biological validation, and informatics, strengthens an already powerful drug discovery platform, and accelerates the pace of our drug discovery pipeline."
Peter Lamb, Ph.D., brings significant knowledge and proficiency in the development of cell based assays for lead discovery and characterization to Exelixis, Inc. Dr. Lamb most recently served as Director of Transcription Research at Ligand Pharmaceuticals, where he was responsible for the development and implementation of assays for lead characterization, as well as the determination of the mechanism of action of selected compounds.
Kirk McMillan, Ph.D., joins Exelixis from Pharmacopeia, Inc., where he held positions of increasing responsibility, most recently serving as Assistant Director of Drug Discovery. At Pharmacopeia, Dr. McMillan's efforts were concentrated toward assay development, high-throughput screening, and lead optimization, with the goal of identifying compounds for late preclinical and clinical evaluation. Prior to Pharmacopeia, Dr. McMillan worked extensively with human nitric oxide synthase at the University of Texas Health Science Center.
John Nuss, Ph.D., brings considerable experience and expertise in small molecule drug discovery and combinatorial chemistry to Exelixis, Inc. Dr. Nuss most recently served as Director of Organic and Medicinal Chemistry for Chiron Corporation, where he directed discovery efforts in the areas of oncology and diabetes.